BUCHANG PHARMA(SH:603858) Shang Hai Zheng Quan Bao·2025-11-17 20:16Group 1 - The company held a staff representative meeting on November 17, 2025, where Mr. Wu Bing was elected as the staff representative director for the fifth board of directors [1][3] - The new board will consist of Mr. Wu Bing and four other directors elected at the first extraordinary shareholders' meeting in 2025, ensuring that the number of directors who are also senior management or staff representatives does not exceed half of the total board members [1][3] - The election process complied with relevant laws and regulations, and the company confirmed the accuracy and completeness of the announcement [1][4] Group 2 - The first extraordinary shareholders' meeting of 2025 was held on November 17, 2025, with all resolutions passed without any objections [5][6] - The meeting was chaired by the board secretary, and all current directors and supervisors attended, confirming the legality and validity of the meeting [6][9] - Several resolutions were passed, including the cancellation of the supervisory board and adjustments to the number of directors, all requiring a two-thirds majority for special resolutions [7][8] Group 3 - The company announced plans for its subsidiary, Zhejiang Huapai, to invest in a new joint venture, Nanjing Keyinno Biotechnology Co., Ltd., with a registered capital of 2 million yuan [12][13] - Zhejiang Huapai will hold an 11.11% stake in the new company, contributing 222,200 yuan, while other partners will hold the remaining shares [15][16] - This investment is aimed at enhancing business development and research capabilities, aligning with the company's strategic goals without affecting its consolidated financial statements [20]